Search

Your search keyword '"Brociner Marco"' showing total 17 results
Start Over Author "Brociner Marco"
17 results on '"Brociner Marco"'

1. Chromosome 9p trisomy increases stem cells clonogenic potential and fosters T-cell exhaustion in JAK2-mutant myeloproliferative neoplasms

Author

Carretta, Chiara, Parenti, Sandra, Bertesi, Matteo, Rontauroli, Sebastiano, Badii, Filippo, Tavernari, Lara, Genovese, Elena, Malerba, Marica, Papa, Elisa, Sperduti, Samantha, Enzo, Elena, Mirabile, Margherita, Pedrazzi, Francesca, Neroni, Anita, Tombari, Camilla, Mora, Barbara, Maffioli, Margherita, Mondini, Marco, Brociner, Marco, Maccaferri, Monica, Tenedini, Elena, Martinelli, Silvia, Bartalucci, Niccolò, Bianchi, Elisa, Casarini, Livio, Potenza, Leonardo, Luppi, Mario, Tagliafico, Enrico, Guglielmelli, Paola, Simoni, Manuela, Passamonti, Francesco, Norfo, Ruggiero, Vannucchi, Alessandro Maria, and Manfredini, Rossella

Published
2024
Full Text
View/download PDF

2. Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients

Author

Mora, Barbara, Guglielmelli, Paola, Kuykendall, Andrew, Rumi, Elisa, Maffioli, Margherita, Palandri, Francesca, De Stefano, Valerio, Caramella, Marianna, Salmoiraghi, Silvia, Kiladjian, Jean-Jacques, Gotlib, Jason, Iurlo, Alessandra, Cervantes, Francisco, Ruggeri, Marco, Silver, Richard T., Albano, Francesco, Benevolo, Giulia, Ross, David M., Della Porta, Matteo G., Devos, Timothy, Rotunno, Giada, Komrokji, Rami S., Casetti, Ilaria C., Merli, Michele, Brociner, Marco, Caramazza, Domenica, Auteri, Giuseppe, Barbui, Tiziano, Cattaneo, Daniele, Bertù, Lorenza, Arcaini, Luca, Vannucchi, Alessandro M., and Passamonti, Francesco

Published
2022
Full Text
View/download PDF

3. A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis

Author

Maffioli, Margherita, Mora, Barbara, Ball, Somedeb, Iurlo, Alessandra, Elli, Elena Maria, Finazzi, Maria Chiara, Polverelli, Nicola, Rumi, Elisa, Caramella, Marianna, Carraro, Maria Cristina, D'Adda, Mariella, Molteni, Alfredo, Sissa, Cinzia, Lunghi, Francesca, Vismara, Alessandro, Ubezio, Marta, Guidetti, Anna, Caberlon, Sabrina, Anghilieri, Michela, Komrokji, Rami, Cattaneo, Daniele, Della Porta, Matteo Giovanni, Giorgino, Toni, Bertù, Lorenza, Brociner, Marco, Kuykendall, Andrew, and Passamonti, Francesco

Published
2022
Full Text
View/download PDF

4. Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score

Author

Barbui, Tiziano, Ghirardi, Arianna, Carobbio, Alessandra, Masciulli, Arianna, Carioli, Greta, Rambaldi, Alessandro, Finazzi, Maria Chiara, Bellini, Marta, Rumi, Elisa, Vanni, Daniele, Borsani, Oscar, Passamonti, Francesco, Mora, Barbara, Brociner, Marco, Guglielmelli, Paola, Paoli, Chiara, Alvarez-Larran, Alberto, Triguero, Ana, Garrote, Marta, Pettersson, Helna, Andréasson, Björn, Barosi, Giovanni, and Vannucchi, Alessandro Maria

Published
2022
Full Text
View/download PDF

5. Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation

Author

Salvini, Marco, Maggi, Fabrizio, Damonte, Camilla, Mortara, Lorenzo, Bruno, Antonino, Mora, Barbara, Brociner, Marco, Mattarucchi, Roberta, Ingrassia, Alessia, Sirocchi, Davide, Bianchi, Benedetta, Agnoli, Stefania, Gallazzi, Matteo, Merli, Michele, Ferrario, Andrea, Bombelli, Raffaella, Barraco, Daniela, Baj, Andreina, Bertù, Lorenza, Grossi, Paolo A., and Passamonti, Francesco

Published
2022
Full Text
View/download PDF

8. A Population-Based Study on Survival of Higher Risks Myelofibrosis Patients Treated with Ruxolitinib in the Italian Lombardy Region

Author

Mora, Barbara, primary, Pellegrini, Giacomo, additional, Franchi, Matteo, additional, Maffioli, Margherita, additional, Brociner, Marco, additional, Guglielmelli, Paola, additional, Voso, Maria Teresa, additional, Ottone, Tiziana, additional, Ubezio, Marta, additional, Maggioni, Giulia, additional, Merli, Michele, additional, Vannucchi, Alessandro M., additional, Della Porta, Matteo G., additional, Corrao, Giovanni, additional, and Passamonti, Francesco, additional

Published
2022
Full Text
View/download PDF

9. Immunogenicity and clinical efficacy of anti‐SARS‐CoV‐2 vaccination in patients with hematological malignancies: Results of a prospective cohort study of 365 patients

Author

Salvini, Marco, primary, Damonte, Camilla, additional, Mortara, Lorenzo, additional, Maggi, Fabrizio, additional, Bruno, Antonino, additional, Pellegrini, Giacomo, additional, Mora, Barbara, additional, Brociner, Marco, additional, Ingrassia, Alessia, additional, Mattarucchi, Roberta, additional, Bianchi, Benedetta, additional, Sirocchi, Davide, additional, Agnoli, Stefania, additional, Rumi, Elisa, additional, Merli, Michele, additional, Fossati, Alessandro, additional, Bassi, Susanna, additional, Bombelli, Raffaella, additional, Gallazzi, Matteo, additional, Borsani, Oscar, additional, Baj, Andreina, additional, Franchi, Matteo, additional, Grossi, Paolo A., additional, and Passamonti, Francesco, additional

Published
2022
Full Text
View/download PDF

10. Sequential next generation sequencing analysis in homogeneously treated low risk NPM1‐mutated acute myeloid leukemia with an adverse clinical outcome

Author

Rossi, Marianna, primary, Nizzoli, Maria Elena, additional, Gallì, Anna, additional, Roncoroni, Elisa, additional, Zibellini, Silvia, additional, Merati, Gabriele, additional, Rizzo, Ettore, additional, Rocca, Barbara, additional, Pietra, Daniela, additional, Picone, Cristina, additional, Brociner, Marco, additional, Tobar Cabrera, Claudia Patricia, additional, Gelli, Eleonora, additional, Santacroce, Eugenio, additional, Arcaini, Luca, additional, and Zappasodi, Patrizia, additional

Published
2022
Full Text
View/download PDF

11. The Interaction between IPSS Score and JAK2 Mutation Identifies Patients at Different Vascular Risk in Primary Myelofibrosis

Author

Barbui, Tiziano, primary, Ghirardi, Arianna, additional, Carobbio, Alessandra, additional, Masciulli, Arianna, additional, Carioli, Greta, additional, Rambaldi, Alessandro, additional, Finazzi, Maria Chiara, additional, Bellini, Marta, additional, Rumi, Elisa, additional, Vanni, Daniele, additional, Borsani, Oscar, additional, Passamonti, Francesco, additional, Mora, Barbara, additional, Brociner, Marco, additional, Vannucchi, Alessandro, additional, Guglielmelli, Paola, additional, Paoli, Chiara, additional, Alvarez-Larran, Alberto, additional, Triguero, Ana, additional, Garrote, Marta, additional, Pettersson, Helna, additional, and Andréasson, Björn, additional

Published
2021
Full Text
View/download PDF

12. Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation

Author

Salvini, Marco, primary, Maggi, Fabrizio, additional, Damonte, Camilla, additional, Mortara, Lorenzo, additional, Bruno, Antonino, additional, Mora, Barbara, additional, Brociner, Marco, additional, Mattarucchi, Roberta, additional, Ingrassia, Alessia, additional, Sirocchi, Davide, additional, Bianchi, Benedetta, additional, Agnoli, Stefania, additional, Gallazzi, Matteo, additional, Merli, Michele, additional, Ferrario, Andrea, additional, Bombelli, Raffaella, additional, Barraco, Daniela, additional, Baj, Andreina, additional, Bertù, Lorenza, additional, Grossi, Paolo A., additional, and Passamonti, Francesco, additional

Published
2021
Full Text
View/download PDF

13. P-303 Belantamab mafodotin in patients with relapsed/refractory multiple myeloma who are triple-refractory: a retro-prospective Italian observational study

Author

Offidani, Massimo, Morè, Sonia, Cavo, Michele, Derudas, Daniele, Raimondo, Francesco Di, Cuneo, Antonio, Baldini, Luca, Pepa, Roberta Della, Musso, Maurizio, Boccadoro, Mario, Musto, Pellegrino, Belotti, Angelo, Fioritoni, Francesca, Renzo, Nicola Di, Mele, Anna, Gamberi, Barbara, De Paoli, Lorenzo, Zambello, Renato, Grammatico, Sara, Brociner, Marco, Fazio, Francesca, and Petrucci, Maria-Teresa

Published
2023
Full Text
View/download PDF

14. A risk‐stratification model based on the initial concentration of the serum monoclonal protein andMYD 88mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders

Author

Varettoni, Marzia, primary, Zibellini, Silvia, additional, Boveri, Emanuela, additional, Klersy, Catherine, additional, Candido, Chiara, additional, Rattotti, Sara, additional, Ferretti, Virginia V., additional, Defrancesco, Irene, additional, Mangiacavalli, Silvia, additional, Nizzoli, Maria E., additional, Flospergher, Elena, additional, Zerbi, Caterina, additional, Bergamini, Fabio, additional, Benvenuti, Pietro, additional, Brociner, Marco, additional, Merati, Gabriele, additional, Paulli, Marco, additional, and Arcaini, Luca, additional

Published
2019
Full Text
View/download PDF

15. Whole Body Diffusion Weighted MRI (WB DWI) for the Management of Multiple Myeloma: High Concordance between MRI Diffuse Pattern and BONE Marrow Plasma CELL Infiltration RATE

Author

Brociner Marco, Pietro Benvenuti, Zacchino Michela, Gabriele Merati, Virginia Valeria Ferretti, Marzia Varettoni, Giovanni Savietto, Claudio Salvatore Cartia, Silvia Mangiacavalli, Luca Arcaini, and Sara Rattotti

Subjects
medicine.diagnostic_test, business.industry, Concordance, Immunology, Plasmacytosis, Magnetic resonance imaging, Cell Biology, Hematology, medicine.disease, Biochemistry, Diffuse Pattern, medicine.anatomical_structure, Biopsy, medicine, Bone marrow, business, Nuclear medicine, Multiple myeloma, Diffusion MRI
Abstract

Background: Diffusion-weighted whole body MRI (WB-DWI) is a new functional imaging technique comprising anatomical and functional sequences with an emerging role in the management of multiple myeloma (MM) patients (pts) since it allows highly sensitive detection of diffuse bone marrow (BM) infiltration pattern and focal lesions, avoiding intravenous injections and radiation exposure. The aims of our study were 1) to test the correlation between plasma cells infiltration (BMPC) rate at BM biopsy and the presence of diffuse infiltration pattern at WB-DWI. 2) to compare response according to IMWG criteria and WB-DWI response and to establish the rate of discordancy (WB-DWI progression with increased focal lesions and at least a partial response according to IMWG criteria) Methods: We reviewed data regarding 45 MM patients (pts) observed in our Centre between September 2018 and July 2019 for whom quantification of serum and urine monoclonal component (MC), free light chains value (FLC), BM biopsy, whole body CT scan and WB-DWI data were available at the same time point. Sequential assessment of WB-DWI and laboratory data was available in 20 pts. Patients performed a WB-DWI (Magnetom Area, 1.5T, Siemens Enlarged Germany) for head to knee. The protocol included anatomical sequences T1 and T2 weighted with fat suppression on the sagittal plane specifically for the spine. Coronal T2 weighted fat suppression sequences are performed for the study of femural bone. Axial Dixon T1 weighted sequences of the whole scan region, in breath-old. The functional part is formed by diffusion weighted sequences in the axial plane. MM diagnosis and response were assessed by IMWG criteria. Response were categorized as follows: responsive patients if ≥PR, progressive disease if Results: Table 1 summarizes the clinical and radiological data of the population on study. Median age was 64 years (range 38-86), median number of previous lines of therapy at time of evaluation was 0 (range 0-)2; 47% pts were at the onset, 31% were in follow-up after treatment completion, 22% had progressive disease. WB-DWI showed a diffuse pattern in 22 pts (49%); in 23 patients without a diffuse pattern, 7 (30%) had PBMC >10%; BMPC infiltration rate was significantly higher in pts with presence of diffuse pattern at WB-DWI (p Conclusions: Our study findsa significant correlation between presence of WB-DWI diffuse infiltration patter and BMPC rate, highlighting the possible future use of this radiological technique for monitoring BM residual disease. In addition, this study shows the possible not negligible emergence of discordant pattern of progression, probably deriving from the spatial heterogeneity of MM clones and their different sensitivity to therapy. Disclosures Mangiacavalli: celgene: Consultancy; Janssen cilag: Consultancy; Amgen: Consultancy. Varettoni:Gilead: Other: travel expenses; ABBVIE: Other: travel expenses; Roche: Consultancy; Janssen: Consultancy. Arcaini:Celgene: Speakers Bureau; Celgene, Roche, Janssen-Cilag, Gilead: Other: Travel expenses; Gilead Sciences: Research Funding; Bayer, Celgene, Gilead Sciences, Roche, Sandoz, Janssen-Cilag, VERASTEM: Consultancy.

Published
2019

16. A risk‐stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders

Author

Varettoni, Marzia, Zibellini, Silvia, Boveri, Emanuela, Klersy, Catherine, Candido, Chiara, Rattotti, Sara, Ferretti, Virginia V., Defrancesco, Irene, Mangiacavalli, Silvia, Nizzoli, Maria E., Flospergher, Elena, Zerbi, Caterina, Bergamini, Fabio, Benvenuti, Pietro, Brociner, Marco, Merati, Gabriele, Paulli, Marco, and Arcaini, Luca

Subjects
MONOCLONAL gammopathies, LYMPHOPROLIFERATIVE disorders, BLOOD proteins, G proteins, DISEASE risk factors, CONFIDENCE intervals
Abstract

Summary: IgM monoclonal gammopathies of undetermined significance (IgM MGUS) are associated with a risk of progression to Waldenström macroglobulinaemia (WM) or other lymphoproliferative disorders (LPD) of 1–2% per year. We analysed 176 consecutive patients with IgM MGUS to evaluate risk factors for progression. With a median follow‐up of 83 months (1214 person‐years), 15 patients (8·5%) progressed to WM (n = 14) or marginal zone lymphoma (n = 1). The rate of progression was 1·32% per year (95% confidence interval [CI] 0·80–2·20). The serum monoclonal protein concentration and the MYD88 mutation were independent risk factors for progression (Hazard ratio [HR] 23·3, 95% CI 2·0–273·3, P = 0·012 and HR 24·4, 95% CI 2·2–275·3, P = 0·010, respectively). The cumulative incidence of progression, while considering death as a competing event, was 11·6% at 5 years and 38·0% at 10 years in MYD88‐mutated patients with a serum monoclonal protein of 10 g/l or higher, as compared with 0% at 5 years and 1·1% at 10 years for patients with none or one risk factor. This risk‐stratification model is able to identify a subset of patients with IgM MGUS at high risk of progression to WM or LPD who deserve a lifelong follow‐up. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

17. A bronchoalveolar lavage‐driven antimicrobial treatment improves survival in hematologic malignancy patients with detected lung infiltrates: A prospective multicenter study of the SEIFEM group.

Author

Marchesi, Francesco, Cattaneo, Chiara, Criscuolo, Marianna, Delia, Mario, Dargenio, Michelina, Del Principe, Maria Ilaria, Spadea, Antonio, Fracchiolla, Nicola Stefano, Melillo, Lorella, Perruccio, Katia, Alati, Caterina, Russo, Domenico, Garzia, Mariagrazia, Brociner, Marco, Cefalo, Mariagiovanna, Armiento, Daniele, Cesaro, Simone, Decembrino, Nunzia, Mengarelli, Andrea, and Tumbarello, Mario

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results